<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01485068</url>
  </required_header>
  <id_info>
    <org_study_id>MIN1102</org_study_id>
    <nct_id>NCT01485068</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of the DANUBIO Paclitaxel Eluting Balloon in In-Stent Restenosis Lesions (DEBREST)</brief_title>
  <acronym>DEBREST</acronym>
  <official_title>Assessment of the Safety and Efficacy of the Danubio Paclitaxel-Eluting Balloon for the Treatment of In-Stent Restenosis Lesions in Native Coronary Arteries.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MINVASYS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Cardiovascular Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>MINVASYS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess safety and efficacy of the Danubio Paclitaxel Eluting&#xD;
      Balloon for the treatment of In-Stent Restenosis lesions in native coronary arteries.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The DEBREST clinical trial is a prospective, non-randomized, multicenter, interventional&#xD;
      study evaluating the investigational Danubio Paclitaxel Eluting Coronary Balloon in patients&#xD;
      with in-stent restenosis (ISR) lesion(s) with reference vessel diameter ≥2.5 mm and ≤3.5 mm.&#xD;
      The trial will allow the treatment of up to two ISR (either Bare Metal Stent (BMS) or Drug&#xD;
      Eluting Stent (DES) ISR) per patient in native coronary arteries with mandatory predilatation&#xD;
      with a conventional balloon.&#xD;
&#xD;
      The DEBREST clinical trial will enroll 60 patients. All patients will receive Quantitative&#xD;
      Coronary Angiography (QCA) before and after Drug-Eluting Balloon (DEB) inflation and at 6&#xD;
      months follow-up. All patients will have a clinical follow-up at 1, 6 and 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-stent Late Lumen Loss (mm)</measure>
    <time_frame>6 months post-procedure (up to 26 weeks)</time_frame>
    <description>In-stent Late Lumen Loss by Quantitative Coronary Angiography (QCA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>In-segment Late Lumen Loss (mm)</measure>
    <time_frame>6 months post-procedure (up to 26 weeks)</time_frame>
    <description>In-segment Late Lumen Loss by QCA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic binary restenosis rate (%)</measure>
    <time_frame>6 months post-procedure (up to 26 weeks)</time_frame>
    <description>Angiographic binary restenosis rate (%) by QCA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Event (MACE) rate</measure>
    <time_frame>In-hospital, 1, 6 and 12 months post-procedure.</time_frame>
    <description>MACE defined as death, Myocardial Infarction (MI, Q waves and non-Q waves), emergent cardiac bypass surgery, or any target lesion revascularization (repeat Percutaneous transluminal coronary angioplasty (PTCA) or Coronary artery bypass grafting (CABG)).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically-driven Target Lesion Revascularization (TLR)</measure>
    <time_frame>1, 6 and 12 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Failure (TVF)</measure>
    <time_frame>1, 6 and 12 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization (TVR)</measure>
    <time_frame>1, 6 and 12 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic success</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>In-stent Coronary Artery Restenosis</condition>
  <arm_group>
    <arm_group_label>Danubio</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Danubio paclitaxel-eluting balloon</intervention_name>
    <description>Inflation of the Danubio Paclitaxel Eluting Balloon in in-stent restenosis lesions.</description>
    <arm_group_label>Danubio</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Restenotic lesion in a native coronary artery.&#xD;
&#xD;
          2. First ISR after BMS or DES implantation.&#xD;
&#xD;
          3. Reference diameter &gt; 2.5 and ≤ 3.5mm.&#xD;
&#xD;
          4. Target lesion length: ≤ 21mm.&#xD;
&#xD;
          5. Up to three restenotic lesions per patient.&#xD;
&#xD;
          6. Single restenotic lesion per vessel.&#xD;
&#xD;
          7. The lesion must be treated with the trial device Danubio.&#xD;
&#xD;
          8. During the index procedure, in case of&#xD;
&#xD;
               1. Treatment of a lesion in a vessel other than the target vessel or,&#xD;
&#xD;
               2. Treatment of a lesion in the target vessel proximal or distal to the target&#xD;
                  restenotic lesion, The treatment of the non-target lesion must be successfully&#xD;
                  performed with a Drug-Eluting Stent before the treatment of the target lesion&#xD;
                  (residual stenosis &lt;30%; stent well deployed; no residual dissection; normal TIMI&#xD;
                  flow; no chest pain; ECG unchanged compared to pre-procedural ECG).&#xD;
&#xD;
          9. Successful predilatation with a conventional balloon providing good angiographic&#xD;
             result (i.e. absence of dissection, TIMI &gt; III).&#xD;
&#xD;
         10. The patient is at least 18 years of age.&#xD;
&#xD;
         11. Non menopausal women must provide a negative pregnancy test and use a double&#xD;
             contraception until the end of the study.&#xD;
&#xD;
         12. The patient has clinical evidence of ischemic heart disease, stable or unstable angina&#xD;
             with signs of ischemia, silent ischemia, or a positive functional test.&#xD;
&#xD;
         13. The patient is an acceptable candidate for percutaneous transluminal coronary&#xD;
             angioplasty (PTCA), stenting, and emergent coronary artery bypass graft (CABG)&#xD;
             surgery.&#xD;
&#xD;
         14. The patient or patient's legal representative has been informed of the nature of the&#xD;
             trial and agrees to its provisions and has provided written informed consent as&#xD;
             approved by the Ethics Committee (EC).&#xD;
&#xD;
         15. The patient agrees to return to the same research facility for required angiographic&#xD;
             post-procedure follow-up visit at 6 months .&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Bifurcation lesion(s) including left main.&#xD;
&#xD;
          2. The Danubio covers beyond the lesion proximally and distally with &lt; 2 mm.&#xD;
&#xD;
          3. Heavily calcified lesions.&#xD;
&#xD;
          4. Severe tortuous lesions.&#xD;
&#xD;
          5. Evidence of extensive thrombosis or dissection within target vessel before the&#xD;
             intervention.&#xD;
&#xD;
          6. Documented Left Ventricular Ejection Fraction (LVEF) &lt; 30% at most recent evaluation.&#xD;
&#xD;
          7. A known hypersensitivity or contraindication to aspirin, heparin or bivaluridin,&#xD;
             ticlopidine or clopidogrel, paclitaxel or drugs in similar class, contrast media,&#xD;
             which cannot be adequately pre-medicated.&#xD;
&#xD;
          8. Chronic total occlusion (CTO).&#xD;
&#xD;
          9. A serum creatinine level &gt; 2.0 mg/dL within seven days prior to index procedure.&#xD;
&#xD;
         10. Evidence of an acute MI within 72 hours of the intended index procedure (according to&#xD;
             ARC definition).&#xD;
&#xD;
         11. Planned PCI of any vessel within 30 days post-procedure.&#xD;
&#xD;
         12. Surgery 30 days prior to this PCI or anticipated surgery 6-months post this PCI.&#xD;
&#xD;
         13. During the index procedure, the target lesion requires treatment with a device other&#xD;
             than PTCA prior to use of Danubio (including but not limited to cutting balloon, any&#xD;
             atherectomy, any laser, thrombectomy, etc.).&#xD;
&#xD;
         14. Second restenotic lesion requiring treatment in target vessel.&#xD;
&#xD;
         15. History of a stroke or transient ischemic attack (TIA) within the prior 6 months&#xD;
&#xD;
         16. Active peptic ulcer or upper gastrointestinal (GI) bleeding within the prior 6 months.&#xD;
&#xD;
         17. History of bleeding diathesis or coagulopathy or will refuse blood transfusions.&#xD;
&#xD;
         18. Concurrent medical condition with a life expectancy of less than 12 months.&#xD;
&#xD;
         19. Any previous or planned treatment of the target vessel with anti-restenotic therapies&#xD;
             including, but not limited to brachytherapy.&#xD;
&#xD;
         20. Currently participating in an investigational drug or another device trial that has&#xD;
             not completed the primary endpoint or that clinically interferes with the current&#xD;
             trial endpoints; or requires coronary angiography, IVUS or other coronary artery&#xD;
             imaging procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacques BERLAND, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Saint Hilaire - ROUEN</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Privé d'Antony</name>
      <address>
        <city>Antony</city>
        <zip>92160</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier privé Saint-Martin</name>
      <address>
        <city>Caen</city>
        <zip>14050</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre cardiologique d'Evecquemont</name>
      <address>
        <city>Evecquemont</city>
        <zip>78740</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier d'Haguenau</name>
      <address>
        <city>Haguenau</city>
        <zip>67504</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Les Franciscaines</name>
      <address>
        <city>Nîmes</city>
        <zip>30000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique les Fleurs</name>
      <address>
        <city>Ollioules</city>
        <zip>83192</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Saint-Pierre</name>
      <address>
        <city>Perpignan</city>
        <zip>66012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Saint-Martin</name>
      <address>
        <city>Pessac</city>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <study_first_submitted>November 14, 2011</study_first_submitted>
  <study_first_submitted_qc>December 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2011</study_first_posted>
  <last_update_submitted>April 7, 2015</last_update_submitted>
  <last_update_submitted_qc>April 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Restenosis</keyword>
  <keyword>Paclitaxel-eluting balloon</keyword>
  <keyword>Angioplasty</keyword>
  <keyword>Coronary artery disease</keyword>
  <keyword>Coronary artery stenosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Restenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

